“乙肝导向干扰素”治疗慢性乙型肝炎32例  

32 Cases of Chronic Hepatitis B Treated by Interferon Targeting Therapy

作　　者：张端阳[1] 莫尔敬[1] 高桂英[1] 孙希祥[1] 王伟[1] 

机构地区：[1]空军天津医院,300381

出　　处：《中西医结合肝病杂志》1996年第3期8-10,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：32例慢性乙型肝炎接受导向干扰素(含国产α-干扰素100万单位与乙肝病毒单克隆抗体交联组成)治疗,对照组25例采用干扰素(每支含基因工程干扰素。α-2b 300万单位)治疗,用药次数和疗程相同。结果,乙肝导向干扰素治疗组32例临床治愈22例,治愈率为68.75％,好转8例,好转率为25％,总有效率为93.75％。对照组25例治愈、好转分别为10例和6例,治愈、好转率分别为40％和28％,总有效率为64％。差异显著(P<0.01)。HBV-M变化情况,治疗组HBsAg治疗后阴转4例(12.5％),HBeAg阴转21例(65.6％),抗-HBe阳转16例(50％),HBV-DNA阴转20例(62.5％)。对照组治疗后HBsAg阴转1例(25％),HBeAg阴转12例(48％),抗-HBe阳转8例(32％),HBV-DNA阴转10例(40％),乙肝导向干扰素治疗组优于干扰素对照组(P<0.05或0.01)。32 cases of chronic hepatitis B were terated by alpha interferon mediated by anti-HBs McAb (alpha interferon for targeting therapy of hepatitis B, BT-IFN). One million units (MU) of BT-IFN in treating group and three MU in comparing group each two days intramuscularly for 13 weeks. As a result, 22 cases in the 1st group were cured (68.75%) and 10 cases in the 2 nd group (40%). The difference between two groups has statistical significant (P<0. 01). Loss of HBeAg was seen in 21 of 32 in the 1st group (62. 5%) and 12 of 25 in the 2 nd (48%) (p<0. 05). Loss of HBV DNA was seen in 20 (62 5%) and 10 (40%) in two groups, respectively (P<0. 01). The results above indicate that BT-IFN is an effective, low side-effective and economical drug in treating patients with chronic hepatitis B.

关 键 词：乙型肝炎 乙肝导向干扰素 干扰素 

分 类 号：R512.620.5[医药卫生—内科学] R978.7[医药卫生—临床医学]